FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients with Non-Small-Cell Lung Cancer

INTRODUCTION: The FIR phase II study (NCT01846416) evaluated the efficacy and safety of anti-programmed death-ligand 1 (PD-L1) atezolizumab in advanced non-small-cell lung cancer (NSCLC) selected by tumor cell (TC) or tumor-infiltrating immune cell (IC) PD-L1 expression. METHODS: Patients with PD-L1...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Thorac Oncol
Main Authors: Spigel, David R., Chaft, Jamie E., Gettinger, Scott, Chao, Bo H., Dirix, Luc, Schmid, Peter, Chow, Laura Q. M., Hicks, Rodney J., Leon, Larry, Fredrickson, Jill, Kowanetz, Marcin, Sandler, Alan, Funke, Roel, Rizvi, Naiyer A.
Format: Artigo
Sprog:Inglês
Udgivet: 2018
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7455890/
https://ncbi.nlm.nih.gov/pubmed/29775807
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtho.2018.05.004
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker